Compass Pathways
NASDAQ: CMPS
UK-basedĀ CompassĀ PathwaysĀ areĀ one of the most prolific playersĀ in the emergent psilocybin space,Ā activelyĀ conducting clinical trialsĀ to demonstrate the safety of psilocybin, and its potential to tackle treatment-resistant depression.
Compass IPOād on Friday 18th September, 2020, on the Nasdaq.
The US Food and Drug Administration (FDA) awarded aĀ āBreakthrough TherapyāĀ designationĀ toĀ CompassĀ for their research into the use of psilocybin for severe depression. This allows the Company to accelerate the (usually very slow) development and review of their drugs. Typically,Ā such a designation is only approvedĀ where early evidence suggests the drug in question could pose aĀ significantĀ improvement versus currently-available therapy.
CompassĀ has conducted, and is conducting, a range of registered clinical trials across the world. In the United Kingdom, the Company has worked with theĀ Institute of Psychiatry, Psychology & NeuroscienceĀ (IoPPN) atĀ Kingās College LondonĀ to successfully conduct a double-blind, placebo-controlled study with nearly ninety participants between 18-65 years of age. The study found that psilocybin was well-tolerated by the healthy adult volunteers.
Compass PathwaysĀ has some well-known investors, including Peter Thiel (PayPal co-founder).
Compass’ Patents
Compass has a number of patents pending in the US pertaining to psilocybin.
The Company has an investigational psilocybin formulation dubbed COMP360, which it developed and produces. This is used in Compass’ clinical trials, including a Phase 2 trial evaluating the safety and efficacy of psilocybin in cancer patients with major depressive disorder.
Patents
US10519175B2Ā |Ā GrantedĀ |Ā Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Priority Date: 2017-10-09Ā |Ā Status: Granted 2019-12-31 (expires 2038-10-09)
General Subject Matter: Treating drug resistant depression with crystalline psilocybin in the form Polymorph A
US20200331939Ā |Ā Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Priority Date: 2017-10-09Ā |Ā Status: Pending in US
General Subject Matter: Oral dosage forms of crystalline psilocybin in the form Polymorph A
US20200199161A1Ā |Ā Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Priority Date: 2017-10-09Ā |Ā Status: Pending in US
General Subject Matter: Methods for manufacturing psilocybin from psilocin at greater than 100g scale
